President Donald Trump announced this Friday that he had reached an agreement with nine other pharmaceutical companies to lower some drugs ' rates. The goal is to bring down the costs of some medications while maintaining the same level of quality.
Bristol Myers Squibb, Genentech, Boehringer Ingelheim, Sanofi, Novartis, Merck, Gilead, GSK, and Amgen are the pharmaceutical firms that are working to lower the cost. According to EFE, 14 big pharmaceutical companies have now agreed to value decreases with the Trump administration as a result of these, according to EFE.
In exchange, the nine companies have agreed to pay a three-year suspension of some import tariffs, totaling more than$ 150 billion, in new manufacturing and research and development projects in the United States.
The pharmaceutical firms may donate the active pharmaceutical ingredients, or APIs, needed to make some crucial medications to the nation's emergency stockpile, which Trump established in his first term, according to CNN.
They will provide the medicines through a site.
These companies will offer some of their medicines through a site called TrumpRx as part of the deal reached. According to EFE, the Trump administration may build Go. gov in January, which will direct users to the websites of pharmaceutical companies without using health insurance brokers to intermediary them. The Republican sent letters to 17 major pharmaceutical companies in July requesting that they lower the prices of a number of medications to the level of the "most popular state" system, which sets the lowest price that a product has in similar developed countries. EFE went into detail about how Johnson & Johnson, AbbVie, and Regeneron have now reached voluntary agreements with the Trump administration to prevent them from receiving regulatory behavior. Trump himself stated now at a press conference held at the White House that the three businesses that are still in negotiations, Regeneron, AbbVie, and Johnson & Johnson, will immediately sign a contract with his presidency.
